Evidence map›Paper›PMID 36515236›Full record

ArticleJournal of the American Heart Association2022

A Unique High-Output Cardiac Hypertrophy Phenotype Arising From Low Systemic Vascular Resistance in Cantu Syndrome.

Gautam K Singh, Conor McClenaghan, Manish Aggarwal, Hongjie Gu, Maria S Remedi, Dorothy K Grange, Colin G Nichols

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Treatment of overactive KScientific reports · 2025
    Trial
  2. Article
  3. Article
  4. Bayliss-Starling Prize Lecture: KThe Journal of physiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Non-radioactive RbMethods in molecular biology (Clifton, N.J.) · 2024
    Article
  11. Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome KThe Journal of pharmacology and experimental therapeutics · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gautam K SinghDivision of Cardiology, Department of Pediatrics Washington University School of Medicine St. Louis MO.
Conor McClenaghanCenter for the Investigation of Membrane Excitability Diseases (CIMED) Washington University School of Medicine St. Louis MO.ORCID 0000-0002-0859-3854
Manish AggarwalDivision of Cardiology, Department of Pediatrics Washington University School of Medicine St. Louis MO.ORCID 0000-0003-1073-0376
Hongjie GuDivision of Statistics Washington University School of Medicine St. Louis MO.
Maria S RemediCenter for the Investigation of Membrane Excitability Diseases (CIMED) Washington University School of Medicine St. Louis MO.ORCID 0000-0003-2048-472X
Dorothy K GrangeCenter for the Investigation of Membrane Excitability Diseases (CIMED) Washington University School of Medicine St. Louis MO.ORCID 0000-0001-7425-6322
Colin G NicholsCenter for the Investigation of Membrane Excitability Diseases (CIMED) Washington University School of Medicine St. Louis MO.ORCID 0000-0002-4929-2134
Washington University in St. Louis · US

Funding

Role of vascular KATP channels in Alzheimer’s neurodegeneration and dementiaR35HL140024 · NHLBI · WASHINGTON UNIVERSITY · PI NICHOLS, COLIN G · 2018 to 2023
$5.9M
Electrical excitability in vascular smooth muscle: from rare disease to new paradigmsR00HL150277 · NHLBI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI MCCLENAGHAN, CONOR · 2022 to 2024
$747k
Clinical Trial Readiness for K channel inhibitors in Cantu SyndromeR21HD103347 · NICHD · WASHINGTON UNIVERSITY · PI GRANGE, DOROTHY KATHERINE, NICHOLS, COLIN G · 2020 to 2021
$433k
Electrical excitability in vascular smooth muscle: from rare disease to new paradigmsK99HL150277 · NHLBI · WASHINGTON UNIVERSITY · PI MCCLENAGHAN, CONOR · 2020 to 2021
$200k
NHLBI NIH HHS K99 HL150277NHLBI NIH HHS R00 HL150277NHLBI NIH HHS R35 HL140024NICHD NIH HHS R21 HD103347
6 · The paper itself

Abstract

Background Cardiomegaly caused by left ventricular hypertrophy is a risk factor for development of congestive heart failure, classically associated with decreased systolic and/or diastolic ventricular function. Less attention has been given to the phenotype of left ventricular hypertrophy with enhanced ventricular function and increased cardiac output, which is potentially associated with high-output heart failure. Lack of recognition may pose diagnostic ambiguity and management complexities. Methods and Results We sought to systematically characterize high-output cardiac hypertrophy in subjects with Cantu syndrome (CS), caused by gain-of-function variants in

Indexed as

CardiomegalyHeart FailureHypertrichosisHypertrophy, Left VentricularOsteochondrodysplasiasAdenosine TriphosphateAdolescentAdultChildChild, PreschoolFemaleHumansKATP ChannelsMalePhenotypeVascular ResistanceAdenosine TriphosphateKATP ChannelsABCC9cardiomegalyechocardiographyheart failurehigh‐output state

Identifiers

PMID36515236
PMCPMC9798820
OpenAlexW4311477766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.